Amplify ETFs’ Post

SAFETY NET UNDER ONE ROOF: "Total Consolidation of the 1,500 Gifts Given to ME" A. The City & County of San Francisco: 1. Wealth Management = 27 Firms 2. Hedge Fund = 37 Firms 3. Bank Company = 47 Firms 4. Merrill = $3 trillion = total assets. 5. Bank of America = $3 trillion = total assets. 6. Bank of America = $5 trillion = assets under management. 7. Merrill = $5 trillion = 900 Commercial Companies = assets under management. 8. Pfizer, Inc. Corporation = $8 trillion of profits & sales from pharmaceutical products & medical devices.

Thanks to exchange-traded funds (#ETFs), investors don’t have to be tied to one specific stock. When it comes to #biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle. #investing https://bit.ly/4fS85Sm

The median M&A upfront cash and equity for biopharma transactions on the buy-side has shown significant variation from 2018 to 2024. The most notable spike occurred in the second half of 2021, reaching $412 million. This was followed by a notable increase in the first half of 2024 at $300 million. Other periods displayed lower median values, such as $67 million in the first half of 2020 and $85 million in the second half of 2018. Overall, the trend highlights fluctuating but substantial investment levels in biopharma M&A deals over recent years. Want to see more charts like this? Schedule your demo https://hubs.ly/Q02JjyKF0

I would like to discuss the issues on the November 26 Nikkei Shimbun article, "MBOs to Top 1 Trillion Yen in 2023, Taisho Pharmaceutical and Benesse Following in Succession."

$MOLA - 15 for 1 Split can cause some disturbance for MOLECULIN BIOTECH: About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MOLECULIN BIOTECH recorded a loss per share of 1.31. The entity had not issued any dividends in recent years. The firm had 15:1 split on the 2nd of January 2024. https://lnkd.in/gZ23-XGb #stocks #stocktwits #thematic_portfolio

Ascendis Pharma ($ASND) is a top mover today at 17.0% and is one of the top biotech picks among the largest biotech-focused hedge funds. Go to https://www.ipick.ai/ where you would have seen ASND in the daily gainers list. Then check out the stock page to quickly see the reasons propelling this stock upwards. #investing #investingtips #stocks #stockMarket #biotech #biotechnology

We're voluntarily delisting its common stock (“Common Stock”) from trading on the OTCQB Venture Market. Delisting from the OTCQB Venture Market will have no impact on Company’s Common Shares which will continue to trade on the OTC Pink Open Market providing stockholders the ability to trade their shares in the public market as they can do now. The decision to delist from the OTCQB Venture Market was made to preserve capital for implementing the company’s business plan. As the Company achieves certain milestones, and when conditions are appropriate, it will be prepared to re-engage an auditor and apply to uplist. #CBSC #CBScientificInc #BusinessGrowth #InvestorUpdate #biotechnology #biotech #healthcare #health #technology #innovation #VoluntaryDelisting #OTCQB #OTC #OpenMarket #Stockholder #Businessplan #Milestones #Auditor https://lnkd.in/gx8WhYrP

Discover the latest trends in early-stage biopharma investments with our comprehensive report, "Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective." From Series A financing peaks to the dominance of biologicals and the resurgence of biopharma IPOs, get all the insights you need to stay ahead in the market. 📥 Download your free copy today! 👉 https://ter.li/wtpcs3 #Biopharma #InvestmentTrends #SeriesAFinancing #BeaconData #MarketInsights #InvestmentStrategy

This is a ratio of Nifty Pharma vs Nifty, we invested in the Pharma index fund, in June 2023, and it has given fabulous returns in the past 1 year, much better than the Nifty index fund. I even moved my portfolio to pharma midcap companies, to get better returns. It might give a much better return than the Nifty Index fund in future. Disc- Not a buy or sell recommendation. Past returns are not a guarantee of future returns, and this is especially true for funds. #etf #indexfund #fund #pharma #nifty

Thoughts on this? >> Flagship appears to boost target of 8th fund by up to $500M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #pharmaceutical #biotech